Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 15;387(11):1047-1049.
doi: 10.1056/NEJMc2205944. Epub 2022 Sep 7.

Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19

Annaliesa S Anderson  1 , Patrick Caubel  2 , James M Rusnak  3 ; EPIC-HR Trial Investigators
Affiliations

Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19

Annaliesa S Anderson et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Viral Load Rebound after Covid-19.
Shown are changes in the mean viral load among the study patients who received a course of nirmatrelvir–ritonavir or placebo within 5 days after the onset of symptoms of severe acute respiratory syndrome coronavirus 2 infection (Panel A). Also shown are data for patients with present or persistent viral load rebound in the two groups (Panel B). In Panel B, the lower limit of quantification of the reverse-transcriptase–polymerase-chain-reaction assay was 2 log10 copies per milliliter; the blue line indicates hospitalization of the patient.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gupta K, Strymish J, Stack G, Charness M. Rapid relapse of symptomatic SARS-CoV-2 infection following early suppression with nirmatrelvir/ritonavir. April 26, 2022. (https://assets.researchsquare.com/files/rs-1588371/v1/48342d2c-b3ea-4228...). preprint.
    1. Centers for Disease Control and Prevention Health Alert Network. COVID-19 rebound after Paxlovid treatment. May 24, 2022 (https://emergency.cdc.gov/han/2022/pdf/CDC_HAN_467.pdf).
    1. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med 2022;386:1397-1408. - PMC - PubMed
    1. Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir against mortality, hospitalization, and in-hospital outcomes among community-dwelling, ambulatory COVID-19 patients during the BA.2.2 wave in Hong Kong: an observational study. May 26, 2022. (https://www.medrxiv.org/content/10.1101/2022.05.26.22275631v1). preprint. - PMC - PubMed
    1. Stegger M, Edslev SM, Sieber RN, et al. Occurrence and significance of omicron BA.1 infection followed by BA.2 reinfection. February 22, 2022. (https://www.medrxiv.org/content/10.1101/2022.02.19.22271112v1). preprint.

MeSH terms